Ms Liu Ting ("Ms Liu") was appointed to the Group as CEO of Hainan Blue Code Biotechnology Co., Ltd on 8 October 2024, and redesignated as the Company’s CEO on 16 January 2026. She is responsible for the Group’s strategic direction, corporate development and planning as well as investor relations
A seasoned branding management expert, Ms. Liu has extensive experience in supply chain and operations management. She played a pivotal role in organising the initial entry of leading overseas biotechnology branding products into a well-known e-commerce platform in the Chinese market. Additionally, she has strong connections in the digital marketing sector. With nearly eight years of experience in internet digital marketing, she has conducted extensive research in e-commerce market operations and management, as well as five years of experience in the research and management of biotech anti-aging products.
Ms Liu also boasts nearly eight years of experience in the financial sector, focusing on market management in corporate banking.
Before joining the Group, Ms. Liu served as the Director and CEO of Beijing Peony Century Biotechnology Co., Ltd., where she was involved in product development, brand planning, and overall operational management. She also held the position of Vice President at Northern International Group's Factoring Company.
Ms Liu holds a degree in Financial Management from the University of Macau.
Allen Ewe was officially appointed Group Chief Operating Officer of SDAI Limited on 16 September 2026, overseeing business strategy, operations, market development and regional expansion for the Group’s businesses, including SDAI BioAge Core and QCM iMoxa.
A graduate of Nanyang Technological University, Singapore, with a Bachelor of Engineering (Civil & Structural Engineering) with Honours, Allen brings extensive entrepreneurial and management experience spanning business development, strategic marketing, training, consulting and franchise operations.
Throughout his career, he has founded, managed and advised businesses in Singapore, Malaysia and Australia. His earlier ventures included building retail financial training operations in Singapore and Malaysia, managing OldTown White Coffee franchise outlets in Penang, and establishing business training and consultancy operations serving SMEs. He was recognised with the Creative Young Entrepreneur Award by JCI Malaysia in 2008.
Before taking on his Group COO responsibilities, Allen served as CEO of QCM Holdings Pte Ltd, where he led the establishment of its Singapore operations and regional expansion initiatives across ASEAN.
At SDAI, he focuses on translating innovative health and wellness concepts into commercially scalable businesses through strategic market development, branding, distribution, operational execution and international expansion.
Mr. Tan Wei Chee (“Mr. Tan”) was appointed as the Company’s Chief Financial Officer on 13 May 2026. He is responsible for overseeing the Group’s financial strategy, treasury and taxation functions, financial reporting, as well as corporate and regulatory matters.
A highly accomplished finance professional, Mr. Tan has more than sixteen years of relevant professional experience in auditing, financial management and corporate finance. He began his career with Deloitte & Touche LLP, where he served in the audit practice and was promoted to Audit Manager prior to his departure in 2015.
From 2016 to 2022, Mr. Tan served as the Financial Controller of Biolidics Limited, where he played a key role in the company’s successful listing on the SGX-ST Catalist Board in 2018. Subsequently, from 2022 to 2026, he was the Financial Controller of Clearbridge Health Limited, overseeing the group’s financial reporting, compliance and finance functions.
Mr. Tan holds a Bachelor of Accountancy from Nanyang Technological University and is a Chartered Accountant with the Institute of Singapore Chartered Accountants.
Mr Ng Kheng Jen ("Mr Ken") was appointed as the Company's Acting Chief Financial Officer on 6 May 2024. He is responsible for the Group's financial and management accounting, treasury, taxation, and other corporate and regulatory compliance matters. Subsequently, on 13 May 2026, he was redesignated as the Group’s Financial Controller.
Mr Ken is an accomplished financial executive with a proven track record of strategic leadership and financial expertise. With over nine years of experience in finance and accounting, he has played a pivotal role in driving the financial success of various organisations.
Before joining the Company, Mr Ken was the Acting Group CFO of USP Group Limited, a company listed on the Catalish board of the SGX-ST and the Audit Assistant Manager of Baker Tilly TFW LLP and KPMG PLT.
Mr Ken holds a Degree in Finance and Accounting from Swinburne University of Technology and graduated in March 2015